Somewhat Positive Media Coverage Somewhat Unlikely to Impact RestorGenex Corp. (DFFN) Stock Price

News stories about RestorGenex Corp. (NASDAQ:DFFN) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RestorGenex Corp. earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.1994539222195 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of RestorGenex Corp. (NASDAQ:DFFN) traded down 2.04% on Wednesday, reaching $1.44. 78,366 shares of the company were exchanged. The stock’s market capitalization is $20.19 million. RestorGenex Corp. has a 12-month low of $1.34 and a 12-month high of $15.50. The firm has a 50 day moving average price of $1.68 and a 200-day moving average price of $2.17.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/01/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-restorgenex-corp-dffn-stock-price.html.

About RestorGenex Corp.

Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.

Insider Buying and Selling by Quarter for RestorGenex Corp. (NASDAQ:DFFN)

What are top analysts saying about RestorGenex Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for RestorGenex Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit